Editas Medicine raises $94M in first gene-editing IPO, and then stock price rises Editas Medicine’s entry into the stock market with a $94.4 million initial public offering appears to be sparking positive signals… Read More
Gates-backed Editas Medicine files for IPO, marking CRISPR gene-editing milestone Editas Medicine filed the paperwork for an initial public offering today, marking a first for the growing number of private… Read More
